TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03493269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Orally administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Orally administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: Orally administered 1mg as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Part 1: Orally administered 1mg as a single dose.
Study: NCT01095926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: blood sampling before, during and after doxorubicin administration
Study: NCT01064596

Intervention type: OTHER
Intervention: blood samples
Description: patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
Study: NCT02497339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
Study: NCT01287286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AC-Can
Description: Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
Study: NCT01287286

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
Study: NCT03356665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT)
Description: The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological and molecular tests on DBS
Description: Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
Study: NCT03617133

Intervention type: RADIATION
Group type: OTHER
Intervention: Reduction of vaginal source loading
Description: A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
Study: NCT00457769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and self-generated memory training
Description: Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and self-generated memory training
Description: Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and experimenter-administered memory training
Description: Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and experimenter-administered memory training
Description: Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
Study: NCT02630719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol eye drops
Description: eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Placebo drop
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Asparaginase

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Asparaginase
Study: NCT04133740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Liberal versus conservative oxygen therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Liberal versus conservative oxygen therapy.
Study: NCT04700930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD-Cigarettes
Description: CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
Study: NCT04379349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text messaging - interactive check-in
Description: Interactive SMS text message check-ins delivered once weekly to participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SMS text messaging - inactive control
Description: Minimally interactive SMS text message delivered once weekly to participants.
Study: NCT05110391

Intervention type: DRUG
Intervention: Hormonal Therapy Agent
Description: Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
Study: NCT01247337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine, gemcitabine, cetuximab
Description: Intrahepatic oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine, gemcitabine cetuximab
Description: Oxaliplatin given intravenous
Study: NCT02307565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midodrine
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study: NCT02965248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant systemic chemotherapy
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant systemic chemotherapy
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant systemic chemotherapy
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed
Description: Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Description: Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
Study: NCT04033432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT03010553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection and resection of sentinel lymph node

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection and resection of sentinel lymph node
Study: NCT03110458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-111 100mg
Description: SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-111 200mg
Description: SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
Study: NCT03903900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain
Description: The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
Study: NCT02104648

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RO4602522
Description: Daily oral doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo RO4602522
Description: Daily oral doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo RO4602522
Description: Daily oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Daily oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Daily oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400 mg oral dose given on Day 1 or 11

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Dose given orally on Days 1 and/or 11

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Dose given orally on Days 1 and/or 11
Study: NCT00558363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avodart
Description: 0.5 mg administered orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
Study: NCT02817984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Adipose Tissue (AAT)
Description: The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
Study: NCT01374893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention group will perform the multi-session per day training program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care
Study: NCT00218855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thalidomide
Description: tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thalidomide
Description: tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Study: NCT01132677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20 (Synvisc One)
Description: Single IA injection of 6cc's. Injections will be administered as outlined on the company label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (Corticosteroid)
Description: Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
Study: NCT01350960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 3 weekly SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections
Study: NCT00868192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02520856

Intervention type: OTHER
Intervention: blood sample
Study: NCT00271700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order Set, Education, Feedback
Study: NCT01181375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumour Biopsies and Blood Sampling
Description: Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Asparaginase

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Asparaginase

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial irradiation

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib

Intervention type: DRUG
Group type: OTHER
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine

Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: OTHER
Intervention: VP16

Intervention type: DRUG
Group type: OTHER
Intervention: VP16

Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin (DNR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT04339738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02918071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study: NCT02881086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT03496649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport 500 Unit Powder for Injection
Description: Dysport administered by intramuscular injection